Live·Open questions in longevity research
All news
Science Research

In mice, vascular cells lacking a receptor thought essential for growth acquired venous traits and formed a substantial part of the vascular network

11 November 2026· 261111001

In mice, vascular cells lacking a receptor thought essential for growth acquired venous traits and formed a substantial part of the vascular network

In a Nature paper published on 4 November 2026, Rui Benedito’s group at the National Centre for Cardiovascular Research in Madrid tracked vascular cells lacking the gene for the VEGFR2 receptor alongside normal cells in mice. This receptor receives the signal for blood vessel growth from the protein VEGF. Cells lacking the gene were outcompeted by normal cells at the growing edge of the vascular network, but established themselves in veins and formed a substantial share of the capillaries.

The growth of new blood vessels, or angiogenesis, was thought to require VEGFR2 on endothelial cells, which line the inside of blood vessels: mouse embryos lacking this gene fail to develop blood vessels and die at 8,5–9,5 days of development. The FDA approved the first drug to inhibit tumor blood vessel growth on 26 February 2004, the VEGF-targeting antibody bevacizumab; tumors develop resistance to it over time.

Benedito and colleagues showed in 2012 that retinal vascular cells can grow without VEGFR2 when Notch signaling, which restrains vessel sprouting, is suppressed. Whether a cell lacking VEGFR2 can persist throughout development cannot be tested in mice that lack the gene in every cell, because these mice die early. The laboratory therefore created “mosaic” mice: the gene is switched off at a chosen time in only some vascular cells, which are marked with a different color. The remaining cells are normal, and the organ develops normally.

In the retinas of mouse pups, cells lacking the receptor failed to maintain their position at the growing edge of the network, where VEGF is most abundant: their numbers there fell sharply within three days of gene inactivation, while they continued to divide in veins, where VEGF levels are low. When the gene was switched off on the first day of life, normal cells left the vein for the VEGF-rich edge, while cells lacking the receptor remained in the vein’s main trunk and became predominant there. The vein continually supplies cells that migrate against the direction of blood flow into capillaries. Consequently, by the twentieth day, cells lacking the gene made up most of the capillaries around veins and in the deep vascular layer, which forms in a second wave of growth independently of VEGF. VEGFR2 is required for the first wave of growth, while many subsequent waves originating from veins proceed without it.

Cells that had lost the gene during embryonic development maintained their position at the growing edge better than cells that had lost it recently. A comparison showed that recent gene loss caused little change in gene activity, whereas prolonged loss increased the activity of genes characteristic of veins, particularly Nr2f2, the main regulator of venous development. This set of genes was also activated in capillaries in the heart and lungs; the authors called this reprogramming “venization.” A Nature reviewer suggested that the cells might simply be trapped in the vein; the authors countered that trapped cells could not have formed capillaries in most organs. Cells lacking both VEGFR2 and Nr2f2 expanded less than cells lacking VEGFR2 alone, particularly in veins. The authors conclude that this reprogramming helps the cells grow without VEGFR2.

The adapted cells also increased the activity of PGF and VEGFC, whose proteins activate VEGFR1 and VEGFR3. VEGFR1 partly compensated for VEGFR2 in capillaries, while VEGFR3 did so in arteries: removing these receptors as well reduced the cells’ contribution to these vessels, whereas in veins the cells grew even without all three receptors.

In mice implanted with Lewis lung carcinoma, cells lacking VEGFR2 formed tumor blood vessels but penetrated deep into the tumor less frequently than normal cells. The frequency was lower by a factor of 2,6 for cells that had adapted since embryonic development and by a factor of 5,2 for cells whose gene had been switched off three days before implantation. The authors suggest that such adaptation could also occur in tumor blood vessels. Benedito believes:

“If you block just one pathway, cells find another. A lasting effect requires blocking several pathways at once.”

Originally published on Telegram by Ukhvat NewsView on Telegram
Sources
#vegfr2#angiogenesis#endothelial-cells#venization#vascular-development#tumor-vasculature